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Abstract
Background: Many previous studies have shown the potential therapeutic effect of acupuncture for allergic rhinitis.
Most of these studies, however, were limited by the short duration of observations and lack of sham acupuncture
as the control group. Our preliminary experiments showed that the use of a warm needling achieved a much
more persistent effect in the treatment of allergic rhinitis (AR) compared with simple acupuncture therapy.
Hence, we have designed a multicenter, randomized controlled trial (RCT) in which the first-line medication
loratadine will be used as the control group, and the effect of warm needling therapy will be evaluated through
long-term observation.
Methods/design: The trial is designed as a multicenter, parallel-group, randomized, single-blinded (outcome assessors)
, non-inferiority trial. A total of 98 patients with persistent AR will be randomly assigned into two groups. Patients in the
treatment group will be treated with warm needling at GV14 and acupuncture at EX-HN3, ST2, LI20, EX-HN8, GV23,
LU7, LU5 and LI4 three times a week, for a total of 4 weeks. Patients in the control group will be treated with oral
loratadine 10 mg/day for 4 weeks. The primary outcome will be the change in the Total Nasal Symptom Score (TNSS)
from baseline to that at 6 months after treatment during the follow-up period. The secondary outcomes will include
the Total Non-nasal Symptom Score and the Rhinoconjunctivitis Quality of Life Questionnaire, changes in the TNSS
from baseline to that at 2 and 4 weeks during treatment, and 3 months after treatment during the follow-up period.
Outcomes will be measured at 2 and 4 weeks, and 3 and 6 months after treatment. Any side effects of treatment will
be observed and recorded.
Discussion: We expect that the study results will provide evidence to determine the effects of warm needling
compared with loratadine. Our final goal of the study is to evaluate the difference in the short-term and long-term
effects between the two therapeutic methods, especially the long-term effect of warm needling.
Trial registration: ClinicalTrials.gov NCT02339714. Registered on 14 January 2015.
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Background
Allergic rhinitis (AR) is a symptomatic nasal disorder
resulting from an IgE-mediated immunological reaction
to allergen exposure [1]. AR is a worldwide health prob-
lem affecting people of all ages. The reported incidence
of AR is 11.8–46 % worldwide [2, 3] and 11.1–19.1 % in
China [4, 5]. AR is classified into intermittent allergic
rhinitis (IAR) and persistent allergic rhinitis (PAR) ac-
cording to the time of exposure. The major symptoms
of AR include rhinorrhea, nasal itching, nasal obstruc-
tion, and sneezing. These symptoms can resolve spon-
taneously or with treatment. AR may cause disruption
in sleep cycles and emotional balance, and impair daily
activities [6]. Untreated AR can also trigger other dis-
eases such as bronchial asthma, sinusitis, nasal polyps,
otitis media, and allergic conjunctivitis, resulting in
significant psychological disturbance and economic
burden [7].
The current mainstream medical management of AR
primarily includes allergen avoidance, pharmacotherapy,
immunotherapy and patient education. These treatments,
however, do not always provide complete relief of symp-
toms and are not usually cost-effective, and like other
medications they come with undesirable side effects [8, 9].
Although newer-generation medications have been devel-
oped, the issue of side effects has not been resolved [10].
Furthermore, pharmacotherapy only provides quick
symptom relief in the case of PAR and becomes less
effective in recurrent cases due to the development of
medication tolerance [11]. Immunotherapy can reduce the
natural duration of AR and provide symptom control;
however, it can cause a local or systemic anaphylactic
reaction [12]. Therefore, a safe and long-term effective
treatment modality for AR is needed to provide symptom
relief, regulate immune system function, decrease fre-
quency and severity of AR recurrence, and prevent the
condition from progressing.
The results from our previous international, multicen-
ter clinical study in collaboration with South Korea re-
vealed that 4-week long, active acupuncture treatment
was significantly better at reducing AR symptoms com-
pared with sham acupuncture and non-active treat-
ment [13]. Furthermore, AR symptoms continued to
reduce in the subsequent 4-weeks of follow-up, indicat-
ing the residual effect of acupuncture. Previous studies
have demonstrated that moxibustion has a regulative
effect on immune system function [14, 15]. Conse-
quently, we have optimized the intervention scheme to
warm needling. There are two types of warm needling,
the one we used consists of placing an ignited moxa
stick on the handle of the needle after insertion. Our
hypothesis is that warm needling will achieve equal
or better long-term symptom relief of AR and reduce
its recurrence.
In previous studies of immunotherapy and pharmaco-
therapy effects on AR, the placebo control group treatment
provided over 50 % symptom relief [16]. In previous
clinical studies of AR treated with acupuncture therapy,
placebo acupuncture was widely adopted as the control
group. In this study, however, we have selected western
medicine as the positive control instead of placebo acu-
puncture. Oral antihistamines are usually the first-line
medication for AR symptom relief. Loratadine, as a
second-generation antihistamine agent, has a strong
selective antagonistic effect on the peripheral hista-
mine H1 receptors, providing long-lasting effect with-
out sedating the central nervous system. Not only is
loratadine used in relieving and preventing AR-associated
symptoms such as rhinorrhea, itching, sneezing, nasal
blockage, and ocular symptoms [17, 18], it is also widely
used in the treatment of other allergic diseases. After a de-
tailed evaluation of the desired and the adverse effects, we
chose loratadine as the intervention for the control group.
We have designed a multicenter, randomized con-
trolled trial (RCT) for patients with PAR, using oral lor-
atadine as control. The purpose of this trial is to
answer two questions: (1) is the effect obtained by
warm needling equal to or better than that achieved by
loratadine? and (2) is the treatment of warm needling
safe for patients with PAR?




The trial is designed as multicenter, parallel-group, ran-
domized, single-blinded (outcome assessors), non-
inferiority trial, comparing the differences between warm
needling therapy and loratadine for PAR.
We will recruit 98 patients with PAR from three hos-
pitals in China. According to their group assignment,
patients will receive either 12 sessions of warm needling
or the oral medication loratadine for 4 weeks.
The study design flowchart is presented in Fig. 1, and
the study design schedule is shown in Table 1.
Study population
Trial location
We will recruit patients from three hospitals:
1. Guang’an Men Hospital of China Academy of
Chinese Medical Sciences (CACMS)
2. Acupuncture and Moxibustion Hospital of CACMS
3. Mentougou Hospital of Traditional Chinese
Medicine (TCM).
The three research centers are all situated in the capital
of China.








Randomization of 98 patients
Treatment for 4 weeks
(3 sessions per week)
Evaluations at 4th week
Follow up evaluations at 6th month
Statistical analysis
Baseline evaluations
Treatment for 4 weeks
(10mg per time, once per day)
Fig. 1 Flowchart of the study design
Table 1 Study design schedule
Period Screening Baseline Treatment (W1–4) Follow-up (W5 −M6)
Time W − 1 W0 W2 W4 M3 M6
Eligibility X
Demography and medical history X
Physical examination X
Informed consent X
TNSS X X X X X X
TNNSS X X X X X X
RQLQ X X X X X X
Adverse event X X
Compliance X X X X
RQLQ Rhinoconjunctivitis Quality of Life Questionnaire, TNSS Total Nasal Symptom Score, TNNSS Total Non-nasal Symptom Score
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Inclusion criteria
Participants will be eligible if they meet all of the follow-
ing criteria: (1) are aged 18–60 years, (2) meet the classi-
fication criteria of moderate to severe PAR according to
the Allergic Rhinitis and its Impact on Asthma (ARIA)
guidelines, (3) exhibit at least one positive result on the
allergy skin prick reaction test, (4) a 7-day mean Total
Nasal Symptom Score (TNSS) ≥4 before treatment, and
(5) agree to participate in the study willingly and volun-
tarily and sign the informed consent.
Exclusion criteria
Patients will be excluded if they have any of the following
conditions: (1) suffer from other diseases that have an in-
fluence on PAR symptoms, (2) a moxa smoke allergy, or a
severe needle phobia, (3) have experienced an acute para-
nasal sinusitis or respiratory tract infection within the pre-
vious 2 weeks, (4) a history of chronic paranasal sinusitis
or chronic nasal sinusitis as shown by paranasal sinus
computed tomography examination, or history of organic
nasal cavity disease or nasal cavity surgery, (5) radio-
graphic signs of pulmonary inflammation, (6) paroxysmal
respiratory diseases such as asthma, (7) have taken antihis-
tamines (including H1 and H2 receptor blockers), gluco-
corticoids, decongestants, mast cell membrane stabilizers,
leukotriene antagonists, antibiotics or other prohibited
drugs (including nasal, oral, or ophthalmic usage) or
herbal preparations for AR within the last 2 weeks, (8)
have undergone specific immunotherapy or systematic
hormone therapy within the year prior to enrollment, (9)
have received acupuncture and moxibustion, nasal inhal-
ation of herbal medicine, physical therapy or other exter-
nal treatment for AR within the last 2 weeks, (10) suffer
from a mental disorder, malignant tumor, severe cardio-
vascular disease, severe endocrine disorder, tuberculosis,
hepatitis, or serum creatinine or aspartate transaminase/
alanine transaminase (AST/ALT) above twice the normal
level, and (11) be unable to cooperate in the trial.
Study procedures
Recruitment
In order to achieve the target enrollments of partici-
pants, clinical recruitment flyers were placed in three
hospitals. Clinical recruitment staff will be in charge of
the enrollment process of the 98 participants with PAR.
Participants will be screened based on the inclusive and
exclusive criteria, be briefed on the purpose, procedures,
treatments and possible risks of the trial, and be clearly
inform of their rights to discontinue participation in the
clinical study. The screening process takes about 1 week,
requiring the participants to fill in questionnaires on
symptoms during the 1-week period. Upon participants
signing off the consent forms, the staff will then assign
the recruited patients to different intervention groups.
Randomization
The patients will be randomly assigned in a 1:1 ratio
to the warm needling group or the loratadine group.
The randomization sequence was computer-generated
by the Clinical Evaluation Center of CACMS and the
corresponding group name will be kept in a sealed
and consecutively numbered security envelope. The
envelope will be kept by the recruitment staff of the three
centers. After all patients have signed the informed
consent form, the envelopes will be opened. The pa-
tients will receive either warm needling treatment or
oral medication of loratadine treatment according to
their assigned group.
Blinding
Since the acupuncture group and the medication group
have different characteristics regarding intervening mea-
sures and approaches, it is not feasible to blind both the
operators and patients. Instead we adopted the single-
blinded trial where both the outcome evaluator and stat-
istical analyst will be blinded to the groupings and they
will not be involved in any part of the treatments during
trial to ensure that there no form of bias results. At the
end of the observation period, un-blinding is permissible
only after database blinding approval and data block.
Follow-up
Upon completion of the 4-week treatment period, there
is a further 6-month follow-up period. The research staff
will continue to follow the participants via telephone
communication and short messaging service (SMS). The
frequency of follow-up is monthly and we will keep a
record of the assessment of symptoms and medication
compliance or changes. In the event of participants dis-
continuing or deviating from intervention protocols, the
study staff will record the reasons for this and their
medications and then exclude the participants from the
study, and the latest outcome data including symptoms
and frequency of the attacks.
Intervention
Treatment group
Licensed acupuncture physicians will provide warm
needling treatment three times a week for 4 weeks.
The acupuncture needles are disposable and sterile
and measure 0.25 × 25 mm and 0.25 × 40 mm (Suzhou
Medicine Equipment Co., Ltd., Suzhou, China.). The
moxa stick (Nanyang Lvying Moxibustion Product
Co., Ltd., Nanyang, China) will be pure moxa measur-
ing 12 mm in diameter and 15 mm in length. The acu-
puncture points used will be Dazhui (GV14), Yintang
(EX-HN3), Sibai (ST2), Yingxiang (LI20), Shangying-
xiang (EX-HN8), Shangxing (GV23), Lieque (LU7),
Chize (LU5), and Hegu (LI4), which will be located
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according to the World Health Organization (WHO)
International Standard Acupuncture Points. Patients
will be in the seated position during treatment ses-
sions. After routine skin sterilization, needles will be
inserted using a neutral reinforcing and reduced ma-
nipulation technique. Each needle will be rotated
until the arrival of qi. After the needle is obliquely
inserted at Dazhui (GV14), the moxa stick will be ig-
nited and attached to the needle handle with the ig-
nited end toward the skin 1–1.5 cm from the skin
surface. When the first moxa stick has burnt out, the
ashes will be removed and the second stick will be
replaced following the same procedure. In total, two
moxa sticks are used. All needles will be retained for
30 min. Patients will feel a sense of local warmth,
and the surrounding skin will become mildly red dur-
ing the procedure. All of the practitioners have had
more than 1 year of clinical acupuncture experience
since completing a 5-year-long college of TCM train-
ing. The procedure for conducting warm needling
therapy has been standardized in each center by
training in advance (see Table 2).
Precautions: in the process of inserting the ignited
moxa stick into the needle handle, acupuncture physi-
cians hold the junction of the needle handle and needle
body with one hand while inserting the moxa stick into
the needle at Dazhui (GV14) gently with the other hand
so as to prevent skin burns. After attaching the moxa
stick to the needle handle, acupuncture physicians en-
sure the stick is fully fixed on the needle handle to pre-
vent it from falling on to the skin surface. The patient
will be closely monitored during the entire procedure by
research assistants to ensure safety and that any accident
is handled in a timely manner.
Control group
Loratadine (Shanghai Xianlingbaoya Medicine Co., Ltd.,
Shanghai, China) will be prescribed for oral administration
at a dosage of 10 mg/day in the morning. Each treatment
cycle will be for four consecutive weeks.
Concomitant care and intervention
During the treatment and follow-up period, the subjects
are advised to avoid antigens. The participants are prohib-
ited from taking medications such as oral and intranasal
antihistamines, intranasal steroids, intranasal decongest-
ant, antibiotics or oral leukotriene receptor antagonists.
Only for patients with severe symptoms are intranasal
steroids allowed to be used. The type of medicine, dosage
and usage will be recorded in the diary card for analysis.
For the other complicated chronic diseases, the patients
must continue taking their routine medication and other
therapies. The research staff will record the names of
those diseases and the names of medications and therapies
in the case report.
Discontinuation of the intervention
The intervention is to be terminated in the cases of
severe adverse events, withdrawal of participants by their
own wish and unpermitted medication use.
Outcome measures
It has been found that similar outcomes have been ap-
plied in the previous studies on PAR, such as the Total
Nasal Symptom Score (TNSS), the Total Non-nasal
Symptom Score (TNNSS) [19, 20], the Rhinoconjunctivi-
tis Quality of Life Questionnaire (RQLQ) [21–23], the
Nasal Provocation Test [24], IgE level, eosinophil count
[25], and Visual Analog Scale (VAS) [26]. The TNSS,
TNNSS, and RQLQ have been adopted especially in this
study due to their wide application.
Primary outcome measure
The average change in the TNSS will be measured
blindly by comparing the baseline score in each group
with that at 6 months after treatment during the
follow-up period. The TNSS is determined in terms of
the severity of rhinorrhea, nasal itching, nasal obstruc-
tion, and sneezing.
Secondary outcome measures
The average change in the TNSS will be measured by
comparing the baseline score in each group with that
at 2 and 4 weeks during treatment, 3 months after
treatment during the follow-up period. The average
change in the TNNSS will be reviewed blindly by
comparing the baseline score in each group with that
at 2 and 4 weeks, and 3 and 6 months after treat-
ment. The TNNSS is determined in terms of the sup-
plementary symptoms such as post-nasal discharge,
tearing, nasal or ocular itching, nasal or maxillary
pain, and headache. The RQLQ will be used to
Table 2 Acupoints and needling procedure
Acupoints Angle and direction Depth (mm)
Dazhui (GV14) Oblique insert downwards, then
penetrate towards the acupuncture
point Shenzhu (GV12)
26–32
Yintang (EX-HN3) Transversely, downward 13
Sibai (ST2) Transversely, towards the nose 8
Yingxiang (LI20) Transversely, towards the root of nose 5
Shangyingxiang
(EX-HN8)
Transversely, towards the nose 8
Shangxing (GV23) Transversely, downward 8
Lieque (LU7) Transversely, upward 8
Chize (LU5) Perpendicular, upward 13–21
Hegu (LI4) Perpendicular to the skin 21–26
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observe the effect on patients’ quality of life; this will
also be evaluated at 2 and 4 weeks, and 3 and
6 months after treatment.
All outcome readings will be scored on quantitative
scales, and will be summarized as mean values and
standard deviation.
Safety evaluation of warm needling therapy
Adverse events such as burns, skin rash, pain or
other adverse reactions will be recorded in detail, in-
cluding time of occurrence, duration of symptoms,
severity, management measures, time of adverse reac-
tion disappearance, and any apparent correlation to
the administration of warm needling therapy and/or
medication. Clinical physicians will decide whether to
cease the treatment according to the severity of the
adverse events.
The total study period and the evaluation time points,
see Fig. 2.
Data collection and management
The research staff is responsible for the collection of
baseline characteristic data and the allergen test re-
sults during the screening period. The baseline vari-
ables will include: center location, age, gender, highest
education level achieved, employment, diagnosis, nasal
mucosal examination result, allergen examination re-
sult, typical symptoms, occurrence time of symptoms,
time of recurrence or aggravation, accessory examin-
ation of nasal mucosa and nasal sinus, family history,
relevant diseases (allergic asthma, allergic conjunctiv-
itis), other relevant clinical disorders (such as hyper-
tension, diabetes, and cardiac arrhythmia), as well as
the questionnaires such as the TNSS, the TNNSS,
and the RQLQ.
Participants are required to record in the daily diary
the symptoms of AR and intake of any other medica-
tions during this study period. Outcome evaluators will
examine the outcomes at baseline, 2 weeks (within treat-
ment), 4 weeks (end of treatment), 3 months (within
follow-up), and 6 months (end of follow-up). Data on
nasal symptoms, non-nasal symptoms, and patients’
quality of life will be collected.
Data monitoring and management will be performed
by the Clinical Evaluation Center of CACMS every
3 months. Two assistants will enter all data into an elec-
tronic database by double data entry. The statistical
manager will be responsible for source data organizing,
coding, range checking for data values and converting
data to ensure data quality.
Statistical analysis
Sample size calculation
The sample size calculation was performed with SAS 9.3
software (SAS Institute Inc., Cary, NC, USA) in the Clin-
ical Evaluation Center of CACMS. The mean change in
TNSS before and after treatment was used as the indica-
tor for the efficacy evaluation in the calculation of the
sample size. Results from our previous studies showed
that the mean TNSS change was 4.90 ± 3.54 after acu-
puncture treatment [27] and 3.4 ± 1.0 after loratadine
treatment [28]. Thus, we performed a non-inferiority
test to calculate the appropriate trial sample size with
80 % power, alpha of 0.05, and an acceptable delta of 0.2.
The results showed that a clinically important difference
can be detected by a sample size of at least 39 in each
group. This number was then increased to 49 per group
(total of 98) to allow for a predicted 20-% dropout rate.
Statistical methods
The statistical analysis will be performed with SPSS 17.0
software (SPSS Inc., Chicago, IL, USA) in the Clinical
Evaluation Center of CACMS. We will perform baseline
adjusted analyses for the following variables (the center
and severity), and the baseline value of the correspond-
ing outcomes will be assessed. The data analyses will be
conducted on an intention-to-treat population. Descrip-
tive statistics will be used to compare the baseline mea-
sures and patients’ characteristics between the two
groups. Regarding the primary and secondary outcome
measures, the two-sample t test or Wilcoxon rank sum
test will be used to compare the differences between
the two groups from baseline to the end of treatment
(p < .05 will be considered statistically significant). If an
imbalance occurs in baseline characteristics between the
two groups, ANCOVA will be applied.
Fig. 2 The total study period and the evaluation time points
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Missing data and sensitivity analysis
The data used in the main statistical analysis should be
collected in the fourth week of the treatment and at the
half-year follow-up. In order to avoid missing data, we
will provide an economic compensation for participants
who have finished the trial and provided the completed
data. The investigators have a wealth of experience in
managing patients and collecting data in previous trials.
They record the contact information of participants and
keep in touch with them through a variety of means
during the treatment and follow-up periods.
If the data are not obtained, we will record the time and
reason for the missing data and will analyze the assumed
missing data mechanism. For these missing data, we will
use the multiple imputation adjustment approach. After
the main analysis, we will perform a sensitivity analysis for
the various datasets to enable us to judge the impact of
missing data on our results.
A fully specified statistical analysis plan will be written
independently.
Monitoring
All staff involved in the study must receive training in
advance. The training includes the use of randomized
envelopes, the method for filling out case report forms,
details of the warm needling procedure, the use of
scales, the method for the patients to fill in the diary,
and follow-up visit skills. Staff have been examined after
training to ensure the consistency of warm needling
treatment and the evaluation method.
A special research team from the Clinical Evaluation
Center of CACMS, independent from investigators and
the sponsor, will perform external monitoring of this
study in the three hospitals every 3 months during the
study to ensure the authenticity of the data. An advisory
board will follow the trial and give advice when neces-
sary. The data monitoring committee (DMC) has been
established independent of the sponsor and there is no
conflict of interest. It is responsible for monitoring the
trial progression and guaranteeing the patients’ safety.
We have not specified interim analyses and stopping
plans of the trial, but if the DMC requests interim ana-
lyses, these will be supplied.
In order to improve adherence of the intervention, we
will deliver the medicine once a week to the control
group, and provide free treatment in the treatment group
for 4 weeks. At the end of treatment and follow-up, we
will supply a monetary compensation to the participants
to ensure that treatment and follow-up run to schedule.
Ethics and dissemination
Ethics
This study was designed in accordance with Chinese
corresponding regulations and the principles of the 1996
Declaration of Helsinki, and has been approved by the
Ethics Committee of the Institute of Acupuncture and
Moxibustion of CACMS (201410301), Mentougou Hospital
of TCM (201501151), and the Ethics Committee of
Guang’anmen Hospital, CACMS (2015EC043).
The research assistants will fully explain the purpose,
procedure, treatment and possible risks of the trial, and
clearly inform the patients of their right to discontinue
the study. The participants are required to sign the
informed consent forms before the trial. The research
assistants are in charge of the storage of all the informed
consent forms.
This is the protocol of the second version (v2.0 dated
26 April 2015). On the basis of the first version, the ex-
clusive criteria have been modified slightly in the second
version. All protocol versions have been submitted to
the ethics committees of the three hospitals. Research
ethics committee review board approvals are kept with
the ethics committees of the three hospitals.
Additionally, the participant data and biological speci-
mens obtained in this ongoing research will not to be used
for other purposes. All of the involved personal informa-
tion, such as the informed consent form, the case report
form, the patient diary, and the physical examination find-
ings are stored by category in a specific file cabinet before,
during, and after the trial to protect confidentiality. The
sponsor, statistical manager, and monitoring manager will
have access to the final trial dataset and disclosure of
contractual agreements.
After the trial, if the participants are willing to continue
treatment, we will provide corresponding therapies. For
those who suffer harm from trial participation, we will
provide a certain amount of economic compensation or
free treatment (especially for those with adverse events).
Publications and dissemination
After completing data analysis, publications will be planned
in Chinese and English versions. Regardless of the findings,
we plan to disseminate all of the trial results in conferences
or publications.
All of the staff who participated in the organization,
implementation, data management and data statistical
analysis will be affirmed in the authorship and we do
not intend to use any professional writers.
There is no plan to allow public access to the full
protocol, participant dataset, or statistical code. But, if
necessary, individuals can gain access to the full protocol
through the Ethics Committee of the Institute of Acu-
puncture and Moxibustion of CACMS.
This protocol was written following the Standard
Protocol Items: Recommendations for Interventional trials
(SPIRIT) checklist (see Additional file 1). The future re-
port will follow the Consolidated Standards of Reporting
Trials (CONSORT) guidelines [29], Revised Standards for
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Reporting Interventions in Clinical Trials of Acupuncture
[30], and the extension of CONSORT for reporting non-
inferiority randomized trials [31].
Discussion
The results of this study are expected to provide reliable
evidence for the long-term efficacy of warm needling in
the treatment of PAR.
This trial is designed as a non-inferiority trial. In our
previous study comparing acupuncture and sham-
acupuncture (placebo), the effectiveness of acupuncture
has been proven. Therefore, we chose loratadine as the
control group intervention in this trial so as to compare
the differences between them, whether warm needling
has an equal effect or is better than loratadine. Since
western medicine is clearly being provided to the control
group, with warm needling to the treatment group, it is
difficult for us to achieve blinding of the participants
and operators. Therefore, we chose blinding of the out-
come assessors and the statistical analysts. To reduce
the potential bias, strict random allocation concealment
will be applied to minimize the differences between the
two groups.
In winter, the cold climate, especially in the morning,
is the commonest trigger of AR [32]. In TCM, AR is
differentiated as a deficiency of Wei Qi, caused by ex-
ternal Wind and Cold; due to this pathogenesis of AR,
warm needling at Dazhui (GV14) was included in the
treatment. Moxibustion plays an important role in the
prevention and treatment of disease [33], and previous
research has reported that moxibustion has a positive
effect on RA [34]. Professor Tian Conghuo, the distin-
guished veteran doctor of TCM, has established the
therapeutic method as strengthening yang and expel-
ling Cold for AR. In the treatment, warm needling was
applied at Dazhui (GV14), combining with acupuncture
at local acupoints. Dazhui (GV14) is the confluent acu-
point of the three yang meridians of hand and foot and
the Governor Vessel. Hence, this point is also named as
“yang within yang.” Moxibustion at Dazhui (GV14) acts
by invigorating yang qi of all the yang meridians, promot-
ing the circulation in the Governor Vessel, expelling Cold
and consolidating the defensive qi. Therefore, this acupoint
is especially suitable for the treatment of allergic rhinitis,
asthma, common cold, and the other disorders caused by
yang deficiency [35].
In the preliminary experiment, we conducted a pilot
RCT with a small sample size. The purpose of this pilot
study was to test the feasibility of the trial. Participants
were divided into three groups and accepted warm need-
ling on ginger, acupuncture, and loratadine separately,
20 cases in each groups. The results showed that warm
needling achieved a more persistent effect than acupunc-
ture alone and loratadine alone [27]. As a result, this
multicenter RCT was designed to prove the effect of
warm needling on AR. Considering the complication of
manipulation of warm needling on ginger, we replaced
ginger by increasing the numbers of moxa sticks. The
TNSS at 6-month follow-up was taken as the primary
outcome in this trial.
A previous systematic review of 13 studies showed that
acupuncture was effective at reducing PAR symptoms and
improving patients’ quality of life [36]. However, the dur-
ation of observation in the included studies ranged from
4 weeks to 3 months, and the time of follow-up was short,
resulting in lack of adequate evaluation of the long-term
efficacy of acupuncture and moxibustion. Therefore, the
time of follow-up in our study will be 6 months to ensure
persistent observation of the efficacy maintenance.
We expect that this study results will provide evidence
to determine the effects of warm needling therapy com-
pared to loratadine. Our final goal of this study is to
evaluate differences in the short-term and long-term ef-
fects between the two therapeutic methods, especially
the long-term effect of warm needling therapy.
Trial status
We are beginning to recruit participants for this trial. The
trial is designed to be completed by 31 December 2017.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 80 kb)
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